ClinicalTrials.gg
CompletedNCT00111761Updated Dec 12, 2013Results posted

Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer

A Phase 2 interventional study of Irinotecan and Panitumumab in Colorectal Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-12.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.

Enrollment
59th of 88
43 · median 70
Started
2002
with 2 others
Phase 2
60 of 90
3 open now
Registered
5th of 90
by date
Lead sponsor
20 of 90
Amgen

Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 59th largest by enrollment of the 88 interventional ones that give a count, is one of 3 that started in 2002, is one of 60 in phase 2, and was the 5th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing panitumumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine if panitumumab, in combination with irinotecan, leucovorin, and 5-fluorouracil (5-FU) is safe and efficacious in patients with metastatic colorectal cancer.

Read the detailed description

Indication Metastatic Colorectal Cancer Primary Objective To assess the safety of ABX-EGF in combination with the FOLFIRI regimen in subjects with metastatic colorectal cancer. (The primary objective in the original protocol was to assess progression free survival after treatment with ABX-EGF in combination with the Saltz regimen in subjects with metastatic colorectal cancer).

Secondary Objective(s) To assess the clinical efficacy of ABX-EGF in combination with the FOLFIRI regimen in subjects with metastatic colorectal cancer. (Secondary objectives in the original protocol were to assess safety and additional measures of the clinical efficacy of ABX-EGF in combination with the Saltz regimen in subjects with metastatic colorectal cancer).

To assess the pharmacokinetics (PK) of ABX-EGF in combination with the FOLFIRI regimen in subjects with metastatic colorectal cancer. (Secondary objectives in the original protocol were to assess the PK of ABX-EGF in combination with the Saltz regimen, and the PK of irinotecan (IR) and its active metabolite SN-38 when IR is given in combination with ABX-EGF, leucovorin (LV), and 5-fluorouracil (5-FU) in subjects with metastatic colorectal cancer)

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Immunex
  • Panitumumab
  • ABX-EGF
  • Abgenix
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to comprehend and sign an Institutional Review Board (IRB)-approved form
  • Pathologic diagnosis of colorectal cancer - colorectal adenocarcinoma
  • If history of chemotherapy for colorectal cancer, must have been free of disease for greater than or equal to 1 year after completion of adjuvant chemotherapy
  • Unidimensionally
  • Paraffin-embedded tumor tissue available for immunohistochemistry studies of epidermal growth factor receptor (EGFr) expression (archived tissue is acceptable)
  • Tumor over-expressing EGFr by immunohistochemistry (staining must be the sum of 1+, 2+ and 3+ in greater than or equal to 10% of evaluated tumor cells; staining and evaluation to be conducted at a central laboratory)
  • (ECOG) performance score of 0 or 1
  • Adequate hematologic, renal, and hepatic function

Exclusion criteria

Exclusion Criteria:

  • Female (of , for less than 6 months, not surgically sterilized, or not abstinent) not consenting to use adequate precautions during the course of the study and for 6 months after the last ABX-EGF infusion
  • Female who is breast-feeding or pregnant
  • Any kind of disorder that compromises the ability of the patient to give written and/or comply with the study procedures
  • History of any chronic medical or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, may increase the risks associated with study participation or study drug administration or may interfere with compliance or the interpretation of study results
  • Untreated
  • Therapy for colorectal cancer other than surgery and 5-FU-based therapy
  • Prior treatment for colorectal cancer
  • Prior irinotecan
  • Prior or concurrent radiation therapy for colorectal cancer, including prior adjuvant radiation therapy to the pelvis
  • Known allergy to irinotecan, 5-fluorouracil, or leucovorin
  • Known Gilbert's disease
  • Known dihydropyrimidine dehydrogenase (DPD) deficiency
  • Prior EGFr-targeting agents
  • Use of therapy used with adjuvant intent within 30 days before the first ABX-EGF infusion
  • If prior history of cancer other than colorectal carcinoma, basal cell carcinoma, or cervical carcinoma in situ, no treatment or active disease within 5 years
  • Active inflammatory bowel disease or other bowel disease (other than colorectal carcinoma) causing chronic diarrhea (defined as greater than 4 stools per day)
  • Partial or complete bowel obstruction, known chronic malabsorption, total colectomy, or other major abdominal surgery that might result in substantial alteration in transit to absorption of oral medication
  • Ascites or pleural effusion requiring therapeutic paracentesis or thoracentesis; subject with small, stable, asymptomatic pleural effusions or ascites may be enrolled; subject who has been rendered asymptomatic by successful sclerosis of an effusion may be enrolled.
  • Active interstitial pneumonia or interstitial fibrosis
  • (LVEF) less than 45%, as measured by multiple-gated acquisition (MUGA) scan - Myocardial infarction within 1 year before the first ABX-EGF infusion
  • Any of the following within 6 months before the first study drug dose:

    • Unstable angina;
    • Symptomatic congestive heart failure;
    • Serious uncontrolled cardiac arrhythmia;
    • Cerebrovascular accident or ;
    • Pulmonary embolism;
    • Deep vein thrombosis;
    • Other significant thromboembolic event.
  • Subject known to be (HIV) positive
  • History of any chronic medical or psychiatric condition or laboratory abnormality that, in the opinion of the Investigator, may increase the risks associated with study participation or study drug administration or may interfere with patient compliance or the interpretation of study results
  • Unwilling or unable to comply with study requirements
  • Known allergy to the ingredients of the study drug or to Staphylococcus protein A
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Part 1: Panitumumab + IFL

    Panitumumab (2.5 mg/kg once weekly for up to 48 weeks or until disease progression, intolerable adverse event or other reason for discontinuation) in combination with irinotecan, 5-fluorouracil (5-FU)and leucovorin (IFL chemotherapy regimen)

    Drug: Irinotecan · Biological: Panitumumab · Drug: 5-Fluorouracil · Drug: Leucovorin

  • Experimental
    Part 2: Panitumumab + FOLFIRI

    Panitumumab (2.5 mg/kg once weekly until disease progression, intolerable adverse event or other reason for discontinuation) in combination with irinotecan/5-FU/leucovorin chemotherapy (the FOLFIRI regimen)

    Drug: Irinotecan · Biological: Panitumumab · Drug: 5-Fluorouracil · Drug: Leucovorin

Interventions

  • Part 1: 125 mg/m\^2 IV infusion once a week on weeks 1 through 4 of each 6-week treatment cycle. Part 2: 180 mg/m\^2 IV infusion every other week until disease progression or unable to tolerate.

  • BiologicalPanitumumab

    Intravenous (IV) infusions of panitumumab 2.5 mg/kg once a week delivered in 6-week cycles.

    Also known as: ABX-EGF

  • Part 1: IV bolus 500 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: IV bolus 400 mg/m\^2 and infusional 2400-3000 mg/m\^2 over 46 hours once every other week until disease progression or unable to tolerate.

  • Part 1: IV bolus 20 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: 400 mg/m\^2 every other week until disease progression or unable to tolerate.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 2)

    The number of participants with grade 3 or grade 4 diarrhea in Part 2 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC).

    Time frame: Until disease progression (median 47 weeks)

  2. Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 1)

    The number of participants with grade 3 or grade 4 diarrhea in Part 1 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC).

    Time frame: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first

Secondary outcomes

  1. Number of Participants With an Objective Tumor Response (Part 2)

    Objective tumor response (complete or partial) in Part 2 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease.

    Time frame: Until disease progression (median 47 weeks)

  2. Time to Disease Progression (Part 2)

    Kaplan-Meier estimate of median time from the first dose of study drug to first observed disease progression or death if the death was due to disease progression (whichever comes first) in Part 2 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date.

    Time frame: From enrollment until death or diease progression. Maximum follow-up time was 16 months.

  3. Progression-free Survival Time (Part 2)

    Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 2 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date.

    Time frame: From enrollment until disease progression or death. Maximum follow-up time was 16 months.

  4. Survival Time (Part 2)

    Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date.

    Time frame: From enrollment until death. Maximum follow-up time was 16 months.

  5. Number of Participants Who Died (Part 2)

    The number of participants in Part 2 who died during the study.

    Time frame: From enrollment until last contact. Maximum follow-up was 16 months.

  6. Number of Participants With Objective Tumor Response (Part 1)

    Objective tumor response (complete or partial) in Part 1 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease.

    Time frame: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first

  7. Progression-free Survival Time (Part 1)

    Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 1 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date.

    Time frame: From enrollment until disease progression or death. Maximum follow-up time was 25 months.

  8. Time to Disease Progression (Part 1)

    Kaplan-Meier estimate of the median time from the first dose of study drug to disease progression or death if due to disease progression (whichever comes first) in Part 1 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date.

    Time frame: From enrollment until disease progression or death. Maximum follow-up time was 25 months.

  9. Survival Time (Part 1)

    Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date.

    Time frame: From enrollment until death. Maximum follow-up time was 25 months.

  10. Time to Treatment Failure (Part 1)

    Kaplan-Meier estimate of the median time from the date of first dose of panitumumab or chemotherapy to the date the decision was made to end treatment for any reason in Part 1 of the study.

    Time frame: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first

  11. Time to Initial Objective Tumor Response (Part 1)

    Median time to first observed objective tumor response (complete or partial) among responders in Part 1 of the study.

    Time frame: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first

07

Results

Posted Jun 3, 2011

Participant flow

Participants were enrolled from 19 Jul 2002 through 20 April 2004

Part 1
Participant flow — Part 1
MilestonePanitumumab With FOLFIRIPanitumumab With IFL
Started019
Completed014
Not completed05
Withdrew: Physician decision01
Withdrew: Death02
Withdrew: Other01
Withdrew: Withdrawal by subject01
Part 2
Participant flow — Part 2
MilestonePanitumumab With FOLFIRIPanitumumab With IFL
Started240
Completed160
Not completed80
Withdrew: Adverse event10
Withdrew: Physician decision10
Withdrew: Death10
Withdrew: Disease progression30
Withdrew: Protocol-specified criteria10
Withdrew: Other10

Outcome measures

PrimaryNumber of Participants With Grade 3 or Grade 4 Diarrhea (Part 2)

The number of participants with grade 3 or grade 4 diarrhea in Part 2 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC).

Time frame:
Until disease progression (median 47 weeks)
Reported as:
Number · Participants
Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 2)
ParticipantsPanitumumab With FOLFIRI
Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 2)6
Statistical analysis
  • Panitumumab With FOLFIRI · Percentage of participants: 25.0 · 95% CI 9.8 to 46.7
PrimaryNumber of Participants With Grade 3 or Grade 4 Diarrhea (Part 1)

The number of participants with grade 3 or grade 4 diarrhea in Part 1 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC).

Time frame:
Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
Reported as:
Number · Participants
Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 1)
ParticipantsPanitumumab With IFL
Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 1)11
Statistical analysis
  • Panitumumab With IFL · Percentage of participants: 58 · 95% CI 34 to 80
SecondaryNumber of Participants With an Objective Tumor Response (Part 2)

Objective tumor response (complete or partial) in Part 2 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease.

Time frame:
Until disease progression (median 47 weeks)
Reported as:
Number · Participants
Number of Participants With an Objective Tumor Response (Part 2)
ParticipantsPanitumumab With FOLFIRI
Number of Participants With an Objective Tumor Response (Part 2)8
Statistical analysis
  • Panitumumab With FOLFIRI · Percentage: 33.3 · 95% CI 15.6 to 55.3
SecondaryTime to Disease Progression (Part 2)

Kaplan-Meier estimate of median time from the first dose of study drug to first observed disease progression or death if the death was due to disease progression (whichever comes first) in Part 2 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date.

Time frame:
From enrollment until death or diease progression. Maximum follow-up time was 16 months.
Reported as:
Median · weeks
Time to Disease Progression (Part 2)
weeksPanitumumab With FOLFIRI
Time to Disease Progression (Part 2)47.3 (26.0 to NA)
SecondaryProgression-free Survival Time (Part 2)

Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 2 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date.

Time frame:
From enrollment until disease progression or death. Maximum follow-up time was 16 months.
Reported as:
Median · weeks
Progression-free Survival Time (Part 2)
weeksPanitumumab With FOLFIRI
Progression-free Survival Time (Part 2)41.1 (26.0 to NA)
SecondarySurvival Time (Part 2)

Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date.

Time frame:
From enrollment until death. Maximum follow-up time was 16 months.
Reported as:
Median · weeks
Survival Time (Part 2)
weeksPanitumumab With IFL
Survival Time (Part 2)73.1 (59.4 to NA)
SecondaryNumber of Participants Who Died (Part 2)

The number of participants in Part 2 who died during the study.

Time frame:
From enrollment until last contact. Maximum follow-up was 16 months.
Reported as:
Number · participants
Number of Participants Who Died (Part 2)
participantsPanitumumab With FOLFIRI
Number of Participants Who Died (Part 2)6
SecondaryNumber of Participants With Objective Tumor Response (Part 1)

Objective tumor response (complete or partial) in Part 1 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease.

Time frame:
Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
Reported as:
Number · Participants
Number of Participants With Objective Tumor Response (Part 1)
ParticipantsPanitumumab With IFL
Number of Participants With Objective Tumor Response (Part 1)9
Statistical analysis
  • Panitumumab With IFL · Percentage of participants: 47.4 · 95% CI 24.4 to 71.1
SecondaryProgression-free Survival Time (Part 1)

Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 1 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date.

Time frame:
From enrollment until disease progression or death. Maximum follow-up time was 25 months.
Reported as:
Median · weeks
Progression-free Survival Time (Part 1)
weeksPanitumumab With IFL
Progression-free Survival Time (Part 1)24.3 (19.0 to 36.0)
SecondaryTime to Disease Progression (Part 1)

Kaplan-Meier estimate of the median time from the first dose of study drug to disease progression or death if due to disease progression (whichever comes first) in Part 1 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date.

Time frame:
From enrollment until disease progression or death. Maximum follow-up time was 25 months.
Reported as:
Median · weeks
Time to Disease Progression (Part 1)
weeksPanitumumab With IFL
Time to Disease Progression (Part 1)35.0 (21.7 to 72.0)
SecondarySurvival Time (Part 1)

Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date.

Time frame:
From enrollment until death. Maximum follow-up time was 25 months.
Reported as:
Median · weeks
Survival Time (Part 1)
weeksPanitumumab With IFL
Survival Time (Part 1)73.1 (59.4 to NA)
SecondaryTime to Treatment Failure (Part 1)

Kaplan-Meier estimate of the median time from the date of first dose of panitumumab or chemotherapy to the date the decision was made to end treatment for any reason in Part 1 of the study.

Time frame:
Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
Reported as:
Median · Weeks
Time to Treatment Failure (Part 1)
WeeksPanitumumab With IFL
Time to Treatment Failure (Part 1)24.3 (7.9 to 36.0)
SecondaryTime to Initial Objective Tumor Response (Part 1)

Median time to first observed objective tumor response (complete or partial) among responders in Part 1 of the study.

Time frame:
Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
Reported as:
Median · weeks
Time to Initial Objective Tumor Response (Part 1)
weeksPanitumumab With IFL
Time to Initial Objective Tumor Response (Part 1)5.9 (5.4 to 11.3)

Adverse events

Collected over First dose through maximum of safety FU or 30 days after last dose (median 47 weeks follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab Plus IFL—12/19 (63.2%)19/19 (100%)
Panitumumab Plus FOLFIRI—11/24 (45.8%)24/24 (100%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventPanitumumab Plus IFLPanitumumab Plus FOLFIRI
DiarrhoeaGastrointestinal disorders8/191/24
Febrile neutropeniaBlood and lymphatic system disorders2/190/24
Abdominal painGastrointestinal disorders2/190/24
DehydrationMetabolism and nutrition disorders2/190/24
Chest painGeneral disorders0/192/24
CellulitisInfections and infestations0/192/24
SepsisInfections and infestations0/192/24
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/192/24
Ileus paralyticGastrointestinal disorders1/190/24
Rectal haemorrhageGastrointestinal disorders1/190/24
Most frequent other events
Showing 10 of 184
Most frequent other events
EventPanitumumab Plus IFLPanitumumab Plus FOLFIRI
DiarrhoeaGastrointestinal disorders16/1919/24
FatigueGeneral disorders16/1919/24
RashSkin and subcutaneous tissue disorders16/1919/24
NauseaGastrointestinal disorders13/1915/24
AnorexiaMetabolism and nutrition disorders7/1913/24
VomitingGastrointestinal disorders5/1911/24
Abdominal painGastrointestinal disorders8/198/24
StomatitisGastrointestinal disorders8/196/24
ConstipationGastrointestinal disorders7/1910/24
AlopeciaSkin and subcutaneous tissue disorders6/1910/24

Baseline characteristics

Age Continuous
Age Continuous(Years)Panitumumab With IFLPanitumumab With FOLFIRITotal
Mean56.6 ± 12.160.7 ± 15.058.9 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)Panitumumab With IFLPanitumumab With FOLFIRITotal
Female31013
Male161430
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Panitumumab With IFLPanitumumab With FOLFIRITotal
Asian112
Black or African American437
Hispanic or Latino123
White or Caucasian131831
Other000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Berlin J, Posey J, Tchekmedyian S, Hu E, Chan D, Malik I, Yang L, Amado RG, Hecht JR. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2007 Mar;6(6):427-32. doi: 10.3816/CCC.2007.n.011. PubMed 17531105 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2002, a primary completion of Feb 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2005
First posted
May 26, 2005
Start
Jul 2002
Primary completionActual
Feb 2008
CompletionActual
Oct 2008
Results first posted
Jun 3, 2011
Last update
Dec 12, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00111761
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 26, 2005
Start date
Jul 2002
Primary completion
Feb 2008
Completion
Oct 2008
Results posted
Jun 3, 2011
Last update
Dec 12, 2013

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion